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Abstract To determine the profiles of susceptibility to
antifungal and the genotypes of clinical isolates of
Cryptococcus in Bahia, Brazil, 62 isolates were collected
from cases of meningitis in the period from 2006 to 2010.
Their susceptibilities to fluconazole, itraconazole, ampho-
tericin B and 5-flucytosine were determined by the broth
microdilution technique described by the Clinical and
Laboratory Standards Institute and genotyping of the
URA5 gene was accomplished by restriction fragment
length polymorphism. C. neoformans accounted for 79%
of the identified yeast and C. gattii represented the
remaining 21%. Evaluation of the genotypes determined
that 100% of the C. gattii isolates belong to the VGII
genotype, and 98% of the C. neoformans isolates belong
to the VNI genotype. Determination of susceptibility
revealed isolates resistant to fluconazole (4.8%), 5-
flucytosine (1.6%) and amphotericin B (3.2%); the
stratification of sensitivity results for each species showed
significant differences in susceptibility to azoles. This
study is the first to describe the susceptibility profiles of
molecular and clinical isolates of Cryptococcus in Bahia,
Brazil. The high percentage of C. gattii isolates belonging
to the VGII genotype and its lower susceptibility to
antifungal agents highlight the importance of knowing
which species are involved in cryptococcal infections in
northeastern Brazil.
Introduction
Cryptococcal meningitis, an important opportunistic infec-
tion in HIV-positive patients in developing countries, is
caused by Cryptococcus spp., which are encapsulated
yeasts that are spread worldwide. The genus has two
species most commonly associated with infection in
humans, Cryptococcus neoformans (serotypes A, D and
the AD hybrid; VNI – IV genotypes) and Cryptococcus
gattii (serotypes B and C; VGI – IV genotypes), which
differ genotypically, phenotypically and epidemiologically
[1–3].
Immunocompromised patients are more frequently
infected by C. neoformans, while C. gattii has emerged as
an important cause of infection in immunocompetent
individuals, as illustrated by the recent outbreak on
Vancouver Island (Canada) by the VGII genotype, with
molecular evidence of spread to the northwestern United
States [4–6]. In Brazil, there are few studies that illustrate
the distribution of this genotype [7, 8]. The yeast is
C. S. Matos
Graduate Program in Pharmacy, Faculty of Pharmacy, UFBA,
Salvador, Brazil
A. de Souza Andrade
Program for Scientific Initiation, Faculty of Pharmacy, UFBA,
Salvador, Brazil
N. S. Oliveira
Couto Maia Specialized Hospital,
Salvador, Brazil
T. F. Barros
Department of Clinical and Toxicological Analysis,
Faculty of Pharmacy, UFBA,
Salvador, Brazil
T. F. Barros (*)
College of Pharmacy, Federal University of Bahia,
Street Barão de Jeremoabo, University Campus of Ondina,
Ondina, Salvador, Bahia, Brazil CEP 40170-290
e-mail: tfbarros@uol.com.br
T. F. Barros
e-mail: tfbarros@ufba.br
Eur J Clin Microbiol Infect Dis (2012) 31:1647–1652
DOI 10.1007/s10096-011-1488-3acquired from the environment, and its tropism for the
central nervous system leads to meningitis [9, 10]. The
American Society of Infectious Diseases suggests that the
treatment of cryptococcal meningitis be initiated with an
induction therapy of amphotericin B alone or combined
with 5-flucytosine, followed by consolidation and mainte-
nance therapy with an azole [11].
There are few reports of antifungal resistance in isolates
of Cryptococcus [12–14]. Although some authors suggest
that it remains stable [15–17], the ARTEMIS global
antifungal surveillance study showed increased fungal
resistance to fluconazole. In the period from 1997–2000,
the rate of resistance to fluconazole was 7.3%; in 2005–
2007, this rate increased to 11.7%, with the highest rates
found in Latin America (13.6%) and Africa (12.4%) [18].
The authors propose that the increased resistance may be
limited to areas where antiretroviral therapy is still not
effective, such as Spain [13], Cambodia [12] and Africa
[19, 20].
Little is known about the frequency and susceptibility
profile of Cryptococcus species in northeastern Brazil.
Thus, this study aims to determine the antifungal suscep-
tibility profiles and the frequencies of species and geno-
types of clinical isolates of Cryptococcus spp. in the state of
Bahia in northeastern Brazil.
Materials and methods
Source and identification of clinical isolates
We collected62clinicalisolatesfrom62casesofcryptococcal
meningitisdiagnosed atthe HospitalCoutoMaia,Bahia,from
2006 to 2010. After 48 hours of growth on Sabouraud
dextrose agar (Acumed, New York, NY), the genus was
identified based on the demonstration of typical encapsulated
cells in India ink preparations and the development of brown
pigmentation on the surface of Niger seed agar; classical
biochemical tests were also conducted for the identification of
yeasts[21]. The identification of C. neoformans and C. gattii
was accomplished using canavanine-glycine-bromothymol
blue agar [22]. This study was approved by the ethics
committee of the Hospital Couto Maia.
Reference strains
Cryptococcus complex reference strains were kindly pro-
vided by the Mycology Laboratory of the Institute of
Clinical Research Evandro Chagas - Oswaldo Cruz Foun-
dation and included WM 148 (VNI), WM 626 (VNII), WM
628 (VNII), WM 629 (VNIV), WM 179 (VGI), WM 178
(VGII), WM 161 (VGIII) and WM 779 (VGIV) [23].
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Fig. 1 The distributions of MIC (mg/L) values for fluconazole (a), itraconazole (b), amphotericin B (c) and 5-flucytosine (d) for 62 isolates of
Cryptococcus spp. C. neoformans (empty bars) and C. gattii (black bars)
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tion (ATCC) included Candida parapsilosis 22019 and C.
krusei 6258, which were also used for quality and
reproducibility controls during susceptibility testing.
Antifungal susceptibility tests
The susceptibility tests against fluconazole, itraconazole,
amphotericin B and 5-flucytosine (Sigma Aldrich Quimica
SA, St. Louis, MO) were performed as described in document
M27-A3 of the Clinical and Laboratory Standards Institute
(CLSI) [24]. The minimum inhibitory concentrations (MICs)
were determined by the lowest antifungal agent concentrations
that inhibited 50% fungal growth compared to the control
growth (without antifungal) for fluconazole, itraconazole and
5-flucytosine; the MICs for amphotericin B were determined
by the lowest concentrations that inhibited 100% growth.
DNA extraction
For the extraction of genomic DNA, the mechanical lysis
method was used after digestion of the capsule with urea
buffer [25].
Restriction fragment length polymorphism (RFLP)—URA5
gene
RFLP analysis using the URA5 gene was performed as
described by Meyer and colleagues (2003) using the
primers URA5 (5′ATGTCCTCCCAAGCCCTC
GACTCCG3′)a n dS J 0 1( 5 ′ TTAAGACCTCTGAA
CACCGTACTC3′)[ 23]. RFLP patterns were assigned
visually by comparing them to the patterns obtained from
the standard-type strains (VNI-VNIV and VGI-VGIV).
Statistical analysis
Statistical analysis was performed by the least squares
method using SPSS 17.0 software (SPSS Inc, Chicago,
Illinois). Statistical significance was defined at p<0.05.
Results
All yeasts were characterized as belonging to the genus
Cryptococcus spp., and there were no biochemical differ-
ences among isolates; 79% (49/62) of the isolates were C.
neoformans and 21% (13/62) were C. gattii. The distribu-
tions of the MIC values of the 62 Cryptococcus spp.,
separated by species, to the antifungals tested are shown in
Fig. 1. The antifungal susceptibility profiles are summa-
rized in Table 1, showing isolates of C. neoformans that
were resistant to fluconazole, amphotericin B and 5-
flucytosine and C. gattii isolates that were significantly
resistant to fluconazole.
The URA5 gene RFLP analysis revealed that 98% (48/
49) of isolates of C. neoformans presented the profile of the
molecular genotype VNI and 2% (1/49) of genotype VNII,
Table 1 Susceptibility profiles
and in vitro activities of anti-
fungal agents against clinical
isolates of Cryptococcus spp
S susceptible, S-DD susceptible,
dose-dependent, R resistant
Antifungal agent Species Susceptibility profile % p value*
S S-DD R
Fluconazole C. neoformans 83.7 (41/49) 14.3 (7/49) 2 (1/49) 0.013
C. gattii 38.5 (5/13) 46 (6/13) 15.5 (2/13)
Itraconazole C. neoformans 89.8 (44/49) 10.2 (5/49) 0 0.001
C. gattii 46.1 (6/13) 53.9 (7/13) 0
Amphotericin B C. neoformans 96 (48/49) 0 4 (2/49) 0.622
C. gattii 100 (13/13) 0 0
5-Flucytosine C. neoformans 24.5 (12/49) 7.5 (36/49) 2 (1/49) 0.163
C. gattii 53.9 (7/13) 46.1 (6/13) 0
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Fig. 2 Representative RFLP profiles of the URA5 genes from
Cryptococcus spp. obtained by double-digestion with HhaI and
Sau96I. Lanes 1 and 14 are the molecular markers; lanes 2, 3, 4,
and 5 are genotypes VGI, VGII, VGIII and VGIV, respectively; lanes
6, 7, 8, and 9 are genotypes VNI, VNII, VNII and VNIV, respectively;
lane 10 is the clinical isolate of C. gattii; lanes 11 and 12 are clinical
isolates of C. neoformans; lane 13 is the URA5 gene amplified product
Eur J Clin Microbiol Infect Dis (2012) 31:1647–1652 1649while 100% (13/13) of isolates of C. gattii showed VGII
genotype profile (Fig. 2).
Discussion
The epidemiology of Cryptococcus has been widely studied
around the world, but in Brazil, information regarding the
distribution of species is still fragmentary and incomplete,
reflecting only differences in frequency. Cryptococcosis
caused by C. neoformans is an important cause of
morbidity and mortality in immunocompromised individu-
als worldwide, but the number of published reports of
infection by C. gattii in patients without immunosuppres-
sion is increasing [3–5, 26].
C. gattii was initially considered to be restricted to
tropical and subtropical Australia, Southeast Asia and some
African regions. Currently, however, it is expanding to the
northwest Pacific and North America, which suggests it is
adapting to a new climatic niche or that global warming may
provide favorable conditions for its growth [5, 27, 28]. In
Brazil, the analysis of Cryptococcus spp. isolates from
various regions has shown that C. gattii is significantly
more prevalent in the north-northeast of the country and that
C. neoformans is more prevalent in the south-southeast of
the country; however, there are few studies in the north-
northeast that report the distributions of these pathogens [29].
Santos and colleagues (2008) analyzed the distribution
of species in 56 isolates from 43 patients with meningitis in
the state of Pará and identified a frequency of 35.7% (20/
56) for C. gattii infection [30]. In the southeast, all isolates
from different areas of São Paulo belonged to C. neofor-
mans [31]. However, Almeida and colleagues (2007)
analyzed 83 samples from 38 patients and found only four
isolates of C. gattii from only one patient [32]. In Minas
Gerais, 11.4% of 35 isolates belonged to the species C.
gattii [33]. In the state of Mato Grosso, in the Midwest,
16.6% of 26 samples of 26 cases of cryptococcosis were C.
gattii isolates [34]. These results reveal a high number (13)
of isolates of C. gattii (21%) compared with other studies
[30–34] and suggest that Bahia is an important source of
infection by C. gattii.
Genotypic determination revealed a predominance of the
VNI genotype among C. neoformans isolates, which have
been frequently reported in various regions of the world
[35–40]. All C. gattii isolates belonged to the VGII
genotype. This genotype was reported as the causal agent
of the cryptococcosis outbreak that occurred on Vancouver
Island (BC, Canada) [4, 41]. This genotype has also been
reported in Brazil [7, 8] demonstrating its potential to cause
severe disease in immunocompetent hosts, as it was
recognized as the main agent of a primary cryptococcosis
endemic in the north [29, 30].
The determination of susceptibility profiles revealed the
presence of antifungal-resistant C. neoformans isolates.
Antifungal resistance is among the factors that can contribute
to treatment failure because previous exposure to a risk
factor often leads to resistance [42, 43]. Our findings are
consistent with authors who suggest that there are differences
between C. neoformans and C. gattii sensitivities [44–46],
although others disagree [14, 47, 48]. It is known that an
infection caused by C. gattii has a less favorable response to
antifungal therapy and a relatively worse prognosis com-
pared to infection by C. neoformans [49, 50]; however, the
mechanisms underlying this difference are not clear.
Conclusion
This study is the first to describe the susceptibility profiles of
molecular and clinical isolates of Cryptococcus in Bahia,
Brazil. The high percentage of isolates from the C. gattii
genotype VGII, in addition to its lower susceptibility to
antifungal agents, highlights the importance of knowing the
species involved in cryptococcal infection in this state.
Surveillance studies are needed to elucidate the environmen-
tal niche of this yeast and to monitor trends in antifungal
susceptibility and the distribution of species in Bahia, Brazil.
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